Hercules Capital HTGY 深 沪
等待开盘 08-20 09:30:00 美东时间
25.3416
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 25.3416
- 总市值 0
- 52周最高 25.342
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 23.0945
- 委 比 0.00%
- 总股本 --
- 历史最高 25.342
- 量 比 0
- 振 幅 0.00%
- 历史最低 19.3575
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Heron Therapeutics announces capital restructuring to support growth
Heron Therapeutics (NASDAQ:HRTX) Friday reported the completion of a comprehensive capital restructuring designed to enhance the company's financial flexibility, reduce total debt, and support long-te...
08-08 20:41
JMP Securities Maintains Market Outperform on Hercules Capital, Raises Price Target to $24
JMP Securities analyst Devin Ryan maintains Hercules Capital (NYSE:HTGC) with a Market Outperform and raises the price target from $22 to $24.
08-04 19:58
Hercules Capital Announces Q2 2025 Cash Distribution
Hercules Capital ( ($HTGC) ) has provided an announcement. On July 29, 2025, He...
08-01 05:18
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Ares Capital declares $0.48 dividend
Ares Capital (NASDAQ:ARCC) declares $0.48/share quarterly dividend, in line with previous. Forward yield 8.46% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 15. See ARCC Dividend...
07-29 18:26
Dyne Therapeutics GAAP EPS of -$0.97 misses by $0.01
Dyne Therapeutics press release (NASDAQ:DYN): Q2 GAAP EPS of -$0.97 misses by $0.01. Dyne expects that its existing cash, cash equivalents and marketable securities, including the net proceeds from th...
07-29 04:28
Adaptimmune Limited, A Subsidiary Of Adaptimmune Therapeutics Plc Announces It Entered Into An Asset Purchase Agreement With USWM CT, A Subsidiary Of US WorldMeds Partners, Llc, To Sell Assets And Rights Related To Its Cell Therapy Products Offer Employment To Approximately Half Of Adaptimmune's Workforce. In Exchange, UU WorldMeds Will Pay $55M In Cash
On July 27, 2025, Adaptimmune Limited ("Seller"), a wholly-owned subsidiary of Adaptimmune Therapeutics plc (together with Seller, "Adaptimmune" or the "Company"), entered into an Asset Purchase Agreement (the
07-28 19:49
UBS Maintains Neutral on Hercules Capital, Raises Price Target to $19
UBS analyst Vilas Abraham maintains Hercules Capital (NYSE:HTGC) with a Neutral and raises the price target from $18.5 to $19.
07-16 23:26
Recent Report Shows That Rep. Virginia Foxx Sold Up to $65K Worth of Energy Transfer Stock
July 3, 2025 records indicate that Representative Virginia Foxx filed a sale of...
07-04 23:00
NextTrip files to sell 2.37M shares of common stock by selling shareholders
NextTrip (NTRP) filed a prospectus to resale 2.37 million shares of common stock. The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. This prospectus...
06-21 05:15
